Stockscreener 앱 받기
7.99
0.25%
0.02
시간 외 거래:
8.07
0.08
+1.00%
전일 마감가:
$7.97
열려 있는:
$8.09
하루 거래량:
1.37M
Relative Volume:
0.76
시가총액:
$585.43M
수익:
$31,000
순이익/손실:
$-54.42M
주가수익비율:
-8.1714
EPS:
-0.9778
순현금흐름:
$-48.99M
1주 성능:
-4.31%
1개월 성능:
-8.89%
6개월 성능:
+45.27%
1년 성능:
+61.74%
1일 변동 폭
$7.95
$8.25
1주일 범위
$7.95
$8.92
52주 변동 폭
$4.35
$9.5699
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
7.99 | 627.19M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics eyes year-end BLA after strong prostate cancer data - MSN
trust me - Moomoo
Avoiding Lag: Real-Time Signals in (CADL) Movement - Stock Traders Daily
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish - TradingView
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics, Inc. posts new long term trial results for aglatimagene besadenovec - Traders Union
Candel Therapeutics stock falls despite phase 3 trial publication - Investing.com
CADL Achieves Significant Milestone in Prostate Cancer Treatment - GuruFocus
Candel publishes phase 3 prostate cancer trial results - Investing.com UK
Candel Therapeutics stock falls despite phase 3 trial publication By Investing.com - Investing.com South Africa
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - The Manila Times
Candel publishes phase 3 prostate cancer trial results By Investing.com - Investing.com Australia
Candel Therapeutics Announces Publication in The Lancet - GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bank of America Securities Remains a Hold on Candel Therapeutics (CADL) - The Globe and Mail
New hires at Candel Therapeutics get 63,000 stock options - Stock Titan
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Discipline and Rules-Based Execution in CADL Response - Stock Traders Daily
Candel Therapeutics reported better-than-feared Q1 loss – but all eyes turn to this pivotal event tomorrow - MSN
Candel Therapeutics (CADL) Edges Higher, Holds Above Key Support LevelHigh Dividend Factor - thelegaladvocate.com
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - simplywall.st
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade - MSN
Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data - TradingView
Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs - Traders Union
Behavioral Patterns of CADL and Institutional Flows - Stock Traders Daily
Candel Therapeutics reports positive phase 3 prostate cancer trial data - MSN
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Raises Target Price to $9 - Moomoo
BofA raises Candel Therapeutics stock price target on prostate cancer data - Investing.com UK
BofA raises Candel Therapeutics stock price target on prostate cancer data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data - Dailyhunt
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data - The Globe and Mail
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Candel Therapeutics Inc 주식 (CADL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Option Exercise |
1.29 |
937 |
1,209 |
53,430 |
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
2.60%
0.94%
자본화:
|
볼륨(24시간):